Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Peripheral Stem Cell Transplant and White Blood Cell Transfusions in Treating Patients With Refractory Metastatic Solid Tumors
This study is ongoing, but not recruiting participants.
Study NCT00003839 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Carcinoma of Unknown Primary
Colorectal Cancer
Esophageal Cancer
Gallbladder Cancer
Gastric Cancer
Liver Cancer
Lung Cancer
Pancreatic Cancer
Prostate Cancer
Sarcoma
Additional conditions recognized in this trial
Breast Neoplasms
Carcinoma
Colorectal Neoplasms
Esophageal Diseases
Esophageal Neoplasms
Gallbladder Neoplasms
Liver Neoplasms
Lung Neoplasms
Neoplasms, Unknown Primary
Pancreatic Neoplasms
Prostatic Neoplasms
Stomach Neoplasms
More general conditions related to this trial
Biliary Tract Diseases
Biliary Tract Neoplasms
Breast Diseases
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gallbladder Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Head and Neck Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Liver Diseases
Lung Diseases
Neoplasm Metastasis
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Glandular and Epithelial
Neoplastic Processes
Pancreatic Diseases
Pathologic Processes
Prostatic Diseases
Rectal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Stomach Diseases
Thoracic Neoplasms
Urogenital Neoplasms
Interventions listed in this trial
anti-thymocyte globulin
therapeutic allogeneic lymphocytes
cyclophosphamide
cyclosporine
fludarabine phosphate
Additional drug interventions recognized in this trial
Antilymphocyte Serum
Cyclosporins
Fludarabine
Fludarabine monophosphate
Vidarabine
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Antifungal Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Antiviral Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Heart, Lung, and Blood Institute (NHLBI)
Back to top of Main Content
